GlassScriptPhysician profile
Jennifer Malin
NPI 1134300734
$27,609.02
in general payments reported to CMS, 2019-2025
8 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $19.99 · 2023: $31.80 · 2024: $5,640 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Travel and Lodging: $1,367 · Education: $107 · Food and Beverage: $76.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,606.00 |
| Travel and Lodging | $1,366.53 |
| Education | $107.00 |
| Food and Beverage | $76.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $13,199.65 | 2025 | Enhertu, Datroway |
| Eli Lilly and Company | $7,785.00 | 2025 | |
| Johnson & Johnson Health Care Systems INC. | $6,140.00 | 2024-2025 | Talvey, Tecvayli, Carvykti |
| Genzyme Corporation | $226.95 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $119.20 | 2019 | |
| Emd Serono, INC. | $86.43 | 2019 | |
| Merck Sharp & Dohme LLC | $31.80 | 2023 | Steglujan, Steglatro, Segluromet |
| Kite Pharma, INC. | $19.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Malin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.